DDInter392 DDInter927
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Cladribine {u} (Compound) resembles {v} (Compound) Vidarabine
Cladribine {u} (Compound) resembles {v} (Compound) Nelarabine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Azacitidine
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abacavir
Cladribine {u} (Compound) treats {v} (Disease) hematologic cancer
Cladribine {u} (Compound) binds {v} (Gene) PNP
Cladribine {u} (Compound) upregulates {v} (Gene) RGS2
Cladribine {u} (Compound) downregulates {v} (Gene) PLK1
Cladribine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cladribine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Reserpine
Cladribine (Compound) resembles Vidarabine (Compound)
Cladribine (Compound) resembles Nelarabine (Compound)
Cladribine may lead to a major life threatening interaction when taken with Azacitidine
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Abacavir
Cladribine (Compound) treats hematologic cancer (Disease)
Cladribine (Compound) binds PNP (Gene)
Cladribine (Compound) upregulates RGS2 (Gene)
Cladribine (Compound) downregulates PLK1 (Gene)
Cladribine (Compound) causes Cardiac disorder (Side Effect)
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Reserpine